Evaluation of the effects of ginger consumption on eradication of H.pylori, clinical symptoms, inflammatory factors, and oxidative stress in patients with peptic ulcer

To determine the effects of ginger consumption on eradication of H.pylori, clinical symptoms, inflammatory factors, and oxidative stress in patients with peptic ulcer

A randomized, double-blinded, controlled clinical trial with a parallel group design of 42 patients. Random number table will be used for randomization.

42 eligible patients with peptic ulcer will randomly assign to consume four tablets daily each containing 500 mg of ginger or placebo for six weeks. Both groups will also receive the standard medical treatment in hospital. Patients’ blood samples will be taken before and after the intervention to determine inflamation factors and oxidative stress markers and the two groups will also be compared in eradication of H.pylori and clinical signs. In this study participants and investigators will be blinded and concealment will be done by a third person.

People with a diagnosis of peptic ulcer and in the age range of 18-80 who are able to intake tablets orally and desire to participate in the study will be included in the study. While people having pregnancy or breastfeeding, any history of allergy to ginger, antibiotic use in the last 4 weeks,active alcohol consumption or alcohol, corticosteroid and anticoagulant use,Cardiovascular, liver, lung, kidney diseases ,malignancy, recent surgery will be excluded from the study.

1- intrvention groups: receiving 2g of ginger daily in the form of 500mg tablets for 6 weeks; 2-Plasebo group: placebo tablets for 6 weeks

Eradication of H.pylori; serum IL-8 level, serum TAC level; degree of heartburn and stomach pain; length of indigestion; score of dyspepsia questionnaire

Patients will be randomized into ginger group or placebo according to the table of random numbers at the beginning of the study.

Patients won’t know if they are receiving the ginger or a placebo tablets and for double-blinding the study, the bottles containing the relevant tablets will be concealed as A and B by a third person at the beginning of the study, and none of the research team members will know the type of tablets received by each group.